Barry D. Quart, Director at SYNAGEVA BIOPHARMA CORP (GEVA), sold 1,375 shares at $100.00 ($138K) on 2014-06-20, disclosed to the SEC on 2014-06-24.
Scheduled sale ($138k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KNSA | SELL | 2026-02-12 | $126K | — | Filing → |
| KNSA | SELL | 2026-02-04 | $722K | — | Filing → |
| KNSA | SELL | 2025-12-17 | $1.7M | — | Filing → |